Proteomics International Developing Protein Biomarker-Based Diagnostic for Diabetic Nephropathy | GenomeWeb

By Adam Bonislawski

Australian biotech company Proteomics International has identified a panel of 13 protein biomarkers for the detection of diabetic nephropathy.

The company, which presented the biomarkers at last month's Human Proteome Organization annual meeting in Sydney, is now looking for partners and funding to help it develop the panel as a commercial diagnostic and to explore the potential of some of the markers as drug targets, managing director Richard Lipscombe told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.